Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Balance Sheets

 
  December 31,  
 
  2013   2012  

Assets

             

Current assets:

             

Cash and cash equivalents

  $ 21,155,247   $ 7,629,143  

Cash—restricted

        250,000  

Marketable securities, available-for-sale

    11,299,206     16,368,776  

Accounts receivable

        8,740,000  

Prepaid expenses and other current assets

    968,342     890,123  
           

Total current assets

    33,422,795     33,878,042  

Cash—restricted

    200,000     200,000  

Marketable securities, available-for-sale

        784,156  

Property and equipment, net

    377,996     402,710  

Other assets

    26,963     64,296  
           

Total assets

  $ 34,027,754   $ 35,329,204  
           
           

Liabilities, convertible preferred stock and stockholders' deficit

             

Current liabilities:

             

Notes payable—current portion

  $ 5,281,502   $ 4,420,238  

Accounts payable

    458,511     642,758  

Accrued expenses

    601,509     587,804  

Accrued compensation

    1,099,210      

Interest payable

    76,687     110,625  

Deferred revenue

    2,000,000     943,693  
           

Total current liabilities

    9,517,419     6,705,118  

Deferred rent and lease incentives

    90,782     89,638  

Notes payable

    4,804,176     10,085,678  

Interest payable

    162,222     82,222  

Preferred stock warrant liability

    477,375     720,375  
           

Total liabilities

    15,051,974     17,683,031  

Commitments and contingencies

             

Convertible preferred stock:

             

Convertible Series A-1 preferred stock, $0.0001 par value, 675,000 shares authorized, issued and outstanding at December 31, 2013 and 2012, liquidation preference of $607,500 at December 31, 2013

    675,000     675,000  

Convertible Series A-2 preferred stock, $0.0001 par value, 16,575,000 shares authorized, 16,500,000 issued and outstanding at December 31, 2013 and 2012, liquidation preference of $16,500,000 at December 31, 2013

    16,379,250     16,379,250  

Convertible Series B preferred stock, $0.0001 par value, 151,812,780 shares authorized, 151,112,779 issued and outstanding at December 31, 2013 and 2012, liquidation preference of $64,222,931 at December 31, 2013

    63,964,035     63,964,035  

Convertible Series C preferred stock, $0.0001 par value, 16,700,007 shares authorized, 16,666,673 issued and outstanding at December 31, 2013 and 2012, liquidation preference of $15,000,006 at December 31, 2013

    14,936,553     14,936,553  

Convertible Series D preferred stock, $0.0001 par value, 26,012,500 shares authorized, 25,000,000 issued and outstanding at December 31, 2013 and 2012, liquidation preference of $30,000,000 at December 31, 2013

    29,915,093     29,915,093  

Stockholders' deficit:

             

Common stock, $0.0001 par value, 312,825,000 shares authorized, 13,550,226 and 12,762,614 issued and 13,544,366 and 12,579,744 outstanding at December 31, 2013 and 2012, respectively

    1,355     1,276  

Additional paid in capital

    3,981,926     3,806,487  

Treasury stock

    (938 )   (18,917 )

Accumulated other comprehensive income

    67     2,973  

Accumulated deficit

    (110,876,561 )   (112,015,577 )
           

Total stockholders' deficit

    (106,894,151 )   (108,223,758 )
           

Total liabilities, convertible preferred stock and stockholders' deficit

  $ 34,027,754   $ 35,329,204  
           
           

   

The accompanying notes are an integral part of these financial statements.

F-3